Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FXYD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FXYD1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View FXYD1 Products |
| Gene Delivery | FXYD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View FXYD1 Products |
| Benchmark Ab | Anti-FXYD1 Recombinant Positive Control Sequence-verified reference antibody. |
View FXYD1 Products |
| Validator | FXYD1 siRNA Set For knockdown verification. |
View FXYD1 Products |
| Related Target A | ATP1A1 The alpha-1 subunit of Na+/K+-ATPase, the primary functional partner regulated by FXYD1. |
View ATP1A1 Products |
| Related Target B | FXYD3 Homologous family member; essential for selectivity and counter-screening assays. |
View FXYD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation & Na+/K+-ATPase complex assembly | Lentiviral vectors for stable cell line construction to preserve native membrane topology and subunit association. |
| Subfamily selectivity (avoiding FXYD2/3 off-target) | Recombinant FXYD protein panels strictly verified by mass spectrometry and sequence analysis for counter-screening. |
| Lack of Controls | Sequence-verified benchmark antibodies included as assay positive controls. |
| False Positives | Validated siRNA pools included for target-specific knockdown verification. |
Live FXYD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FXYD1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to peptide mimetics and small-molecule protein-protein interaction (PPI) disruptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific phosphorylation states of FXYD1 to modulate cardiac contractility and tumor metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Academic Medical Centers, Biotech Startups | Heart Failure, Myocardial Ischemia | Selectivity Assay (Need FXYD1 vs FXYD3/4 proteins) |
| Monoclonal Antibody | Oncology-focused Biopharma | Breast Cancer, Melanoma Metastasis | Conformation Validation (Need Lentivirus for Stable Cell Lines) |
| Peptide Therapeutics | Cardiovascular Research Consortia | Cardiac Hypertrophy | Epitope mapping & binding affinity (Need Sequence-Verified ECD-Fc) |